Equities researchers at StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a report released on Saturday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Price Performance
Shares of EVOK stock opened at $0.53 on Friday. The business has a 50-day moving average of $0.49 and a 200 day moving average of $0.65. Evoke Pharma has a 1-year low of $0.40 and a 1-year high of $1.77. The stock has a market capitalization of $4.55 million, a PE ratio of -0.29 and a beta of 0.36.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last released its quarterly earnings data on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.17) earnings per share for the quarter. Evoke Pharma had a negative net margin of 116.75% and a negative return on equity of 4,908.09%. The company had revenue of $1.74 million for the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Further Reading
- Five stocks we like better than Evoke Pharma
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Roth IRA Calculator: Calculate Your Potential Returns
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Where to Find Earnings Call Transcripts
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
